metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P- 23 HEPATOCELLULAR CARCINOMA IN CENTRAL AMERICA: EPIDEMIOLOGY OF A COSTA RICAN...
Journal Information
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Full text access
P- 23 HEPATOCELLULAR CARCINOMA IN CENTRAL AMERICA: EPIDEMIOLOGY OF A COSTA RICAN COHORT
Visits
212
Francisco Vargas, María Lynch, María Castro, Aldo Carvajal, Esteban Cob, Victor Alvarado, Daniel Mondragón, Alejandra Ochoa, Bruno Solís, Vanessa López, Sheyla Araya, Irene Mora, Silvia Alfaro, Dionisio Flores, Allan Ramos-Esquivel, Gerardo Avendaño, Pablo Coste
Liver Unit, Hospital R.A. Calderón Guardia, Caja Costarricense del Seguro Social, San José, Costa Rica
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S1

Abstracts of the 2023 Annual Meeting of the ALEH

More info
Introduction and Objectives

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide and a major problem in Latin America. It is characterized by significant epidemiological heterogeneity, but most data come from resource-rich countries. This is the largest cohort to date reporting HCC characteristics and outcomes in Central America.

Materials and Methods

Retrospective analysis of a cohort of HCC diagnosed radiographically or histologically and analysis of daily practice from a specialized Costa Rican center.

Results

From 10/2018 to 03/2023, 200 patients with HCC were evaluated. The median age at diagnosis was 67 years and 61% were men. The most common etiologies were NAFLD, alcohol, viral hepatitis, and autoimmune hepatitis (63, 22, 5 HBV, 4 HCV, and 3%, respectively), 67% had arterial hypertension, and 60% DM2. Diagnosis was 55% incidental (53% ultrasonography and 2% CT/MRI), 45% during surveillance (40% US, 3.5% CT/MRI and 1.5% AFP increase with negative US) and 42% had a significant elevation of AFP (20 ug/L). Child-Pugh Score was 54, 33 and 6% for A, B and C respectively and 7% were non-cirrhotic (71% NAFLD). The modified BCLC staging system for HCC in cirrhotic liver was 3, 46, 17, 22, and 12% for stage 0, A, B, C, and D, respectively. Being diagnosed during surveillance was significantly associated with a curable BCLC stage (0 or A) (p=0.003) but not with better overall survival (p=0.18).

Conclusions

This study represents the largest cohort to date reporting HCC characteristics in Central America. Most HCCs are diagnosed incidentally and in a non-curable stage. Health policies should be directed based on the epidemiological factors identified in order to reduce the mortality of these patients.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos